Table 3.
The serum of miR-10b-3p expression status and clinicopathological characteristics of patients with ESCC
| Characteristics | miR-10b-3p expression status | ||
|---|---|---|---|
| Low (n = 46) | High (n = 46) | P | |
| Gender | |||
| Male | 33 (47.8%) | 36 (52.2%) | 0.470 |
| Female | 13 (56.5%) | 10 (43.5%) | |
| Age | |||
| <60 | 19 (44.2%) | 24 (55.8%) | 0.296 |
| ≥ 60 | 27 (55.1%) | 22 (44.9%) | |
| Tumor size | |||
| < 5 cm | 31 (51.7%) | 29 (77.5%) | 0.662 |
| ≥ 5 cm | 15 (22.5%) | 17 (22.5%) | |
| Tumor stage | |||
| T1+ T2 | 18 (60.0%) | 12 (40.0%) | 0.182 |
| T3+ T4 | 28 (45.2%) | 34 (54.8%) | |
| Histological grade | |||
| Well/moderate | 36 (53.7%) | 31 (46.3%) | 0.241 |
| Poor/NS | 10 (40.0%) | 15 (60.0%) | |
| Lymph node metastasis | |||
| Negative | 26 (65.0%) | 14 (35.0%) | 0.012 |
| Positive | 20 (38.5%) | 32 (61.5%) | |
| Clinical stages | |||
| I + II | 37 (69.8%) | 16 (30.2%) | 0.000 |
| III + IV | 9 (23.1%) | 30 (76.9%) | |